var data={"title":"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/contributors\" class=\"contributor contributor_credentials\">Fernando C Fervenza, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/contributors\" class=\"contributor contributor_credentials\">Sanjeev Sethi, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/contributors\" class=\"contributor contributor_credentials\">Richard J Glassock, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/contributors\" class=\"contributor contributor_credentials\">Albert Q Lam, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 02, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1217072877\"><span class=\"h1\">INTRODUCTION AND CLINICAL PRESENTATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Membranoproliferative glomerulonephritis (MPGN) is a pattern of glomerular injury on renal biopsy with characteristic light microscopic changes. The clinical presentation is similar to that in other types of glomerulonephritis. In patients with active disease, the urine sediment reveals hematuria, typically with dysmorphic red cells (<a href=\"image.htm?imageKey=NEPH%2F79440\" class=\"graphic graphic_picture graphicRef79440 \">picture 1</a> and <a href=\"image.htm?imageKey=NEPH%2F62064\" class=\"graphic graphic_picture graphicRef62064 \">picture 2</a>) and occasionally with red cell casts (<a href=\"image.htm?imageKey=NEPH%2F55778\" class=\"graphic graphic_picture graphicRef55778 \">picture 3</a>); there is a variable degree of proteinuria; and the serum creatinine may be normal or elevated. Occasional patients with indolent disease present late in the course at a time when active inflammation has subsided. Such patients may have a bland urine sediment with a variable degree of proteinuria and elevation in serum creatinine. The diagnosis is made by renal biopsy [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=glomerular-disease-evaluation-and-differential-diagnosis-in-adults\" class=\"medical medical_review\">&quot;Glomerular disease: Evaluation and differential diagnosis in adults&quot;</a> and <a href=\"topic.htm?path=etiology-and-evaluation-of-hematuria-in-adults#H10\" class=\"medical medical_review\">&quot;Etiology and evaluation of hematuria in adults&quot;, section on 'Glomerular versus nonglomerular bleeding'</a>.)</p><p>As will be described below, there are two major types of MPGN, which are based upon immunofluorescence microscopy: immune complex-mediated and complement-mediated. Hypocomplementemia is common in all types of MPGN [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/2-6\" class=\"abstract_t\">2-6</a>]. In immune complex-mediated MPGN, complement activation occurs via the classic pathway and is typically manifested by a normal or mildly decreased serum C3 concentration and a low serum C4 concentration. In complement-mediated MPGN, there are usually low serum C3 and normal C4 levels due to activation of the alternate pathway [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/3\" class=\"abstract_t\">3</a>]. However, complement-mediated MPGN is not excluded by a normal serum C3 concentration, and it is not unusual to find a normal C3 concentration in adults with dense deposit disease (DDD) [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/6\" class=\"abstract_t\">6</a>] or C3 glomerulonephritis (C3GN). (See <a href=\"#H12\" class=\"local\">'Complement-mediated MPGN'</a> below.)</p><p>Among patients who have the different forms of MPGN described below, there are generally no differences in clinical presentation with the possible exception of patients with DDD, which is a form of complement-mediated MPGN that is associated with drusen formation that may be seen on fundoscopic examination and with partial lipodystrophy. (See <a href=\"topic.htm?path=c3-glomerulopathies-dense-deposit-disease-and-c3-glomerulonephritis#H6\" class=\"medical medical_review\">&quot;C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis&quot;, section on 'Extrarenal abnormalities'</a>.)</p><p>This topic will review the pathology and pathogenesis of MPGN, a proposed classification based upon immunofluorescence microscopy, the original classification of MPGN based upon electron microscopy (EM), and the limitations of this approach. The treatments of the different types of MPGN, including recurrent MPGN following renal transplantation, are discussed elsewhere. (See <a href=\"topic.htm?path=evaluation-and-treatment-of-membranoproliferative-glomerulonephritis\" class=\"medical medical_review\">&quot;Evaluation and treatment of membranoproliferative glomerulonephritis&quot;</a> and <a href=\"topic.htm?path=c3-glomerulopathies-dense-deposit-disease-and-c3-glomerulonephritis\" class=\"medical medical_review\">&quot;C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis&quot;</a> and <a href=\"topic.htm?path=recurrence-of-idiopathic-immune-complex-mediated-membranoproliferative-glomerulonephritis-mpgn-after-transplantation\" class=\"medical medical_review\">&quot;Recurrence of idiopathic immune complex-mediated membranoproliferative glomerulonephritis (MPGN) after transplantation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">PATHOLOGY AND PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>MPGN, also known as mesangiocapillary glomerulonephritis, is a pattern of glomerular injury on light microscopy that is characterized by mesangial hypercellularity, endocapillary proliferation, and double-contour formation along the glomerular capillary walls (<a href=\"image.htm?imageKey=NEPH%2F67999%7ENEPH%2F78967\" class=\"graphic graphic_picture graphicRef67999 graphicRef78967 \">picture 4A-B</a>). The term &quot;MPGN&quot; is derived from the two characteristic histologic changes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thickened glomerular basement membrane (GBM) due to deposition of immune complexes <span class=\"nowrap\">and/or</span> complement factors, interposition of the mesangial cell and other cellular elements between the GBM and the endothelial cell, and new basement membrane formation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased mesangial and endocapillary cellularity, often leading to a lobular appearance of the glomerular tuft. The increase in cellularity results from both proliferation of mesangial cells and influx of circulating monocytes. </p><p/><p>Two primary mechanisms have been described in the pathogenesis of MPGN:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immune complex deposition leading to activation of complement (immune complex-mediated) (see <a href=\"#H455985606\" class=\"local\">'Immune complex-mediated MPGN'</a> below)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dysregulation and persistent activation of the alternative complement pathway (complement-mediated) (see <a href=\"#H12\" class=\"local\">'Complement-mediated MPGN'</a> below)</p><p/><p class=\"headingAnchor\" id=\"H981933439\"><span class=\"h1\">CLASSIFICATION BASED UPON IMMUNOFLUORESCENCE MICROSCOPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>MPGN has traditionally been classified as MPGN types I, II, and III based upon electron microscopic findings. However, advances in the understanding of processes involved in the pathogenesis of MPGN suggest that the electron microscopy (EM)-based classification can result in overlap among the types (<a href=\"image.htm?imageKey=NEPH%2F86556\" class=\"graphic graphic_algorithm graphicRef86556 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"#H559999613\" class=\"local\">'Classification based upon electron microscopy'</a> below.)</p><p>By contrast, a classification that is based upon the pathogenetic process helps to direct the clinical evaluation and to provide disease-specific treatments. In this system, MPGN is classified as being mediated by immune complexes, by complement dysregulation that leads to persistent activation of the alternative complement pathway, or rarely, by mechanisms not involving immunoglobulin or complement deposition, such as endothelial injury [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/7\" class=\"abstract_t\">7</a>]. These disorders can be distinguished by immunofluorescence microscopy [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/8,9\" class=\"abstract_t\">8,9</a>].</p><p>Immune complex-mediated MPGN is characterized by the presence of immune complexes and complement components, while complement-mediated MPGN is characterized by the presence of complement components in the absence of immune complexes.</p><p class=\"headingAnchor\" id=\"H455985606\"><span class=\"h2\">Immune complex-mediated MPGN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immune complex-mediated MPGN results from chronic antigenemia <span class=\"nowrap\">and/or</span> circulating immune complexes and can be seen in chronic infections, autoimmune diseases, and monoclonal gammopathies [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/10-19\" class=\"abstract_t\">10-19</a>]. An underlying cause can be found in the majority of cases [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/8,9,20\" class=\"abstract_t\">8,9,20</a>].</p><p>Immunofluorescence microscopy may suggest the underlying etiology of immune complex-mediated MPGN: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>MPGN resulting from hepatitis C virus infection typically shows granular deposition of immunoglobulin M (IgM), C3, and <strong>both</strong> kappa and lambda light chains. IgG may or may not be present, and C1q is typically negative. This pattern may also be seen with MPGN induced by other viral infections [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/2\" class=\"abstract_t\">2</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>MPGN resulting from monoclonal gammopathy is characterized by deposition of monotypic kappa or lambda light chains <strong>but not both</strong>. MPGN associated with heavy-chain deposition may show immunoglobulin deposition (heavy-chain isotypes) in the absence of either light chain [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/17\" class=\"abstract_t\">17</a>]. (See <a href=\"#H455985660\" class=\"local\">'Monoclonal gammopathies'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>MPGN resulting from autoimmune diseases is typically characterized by the &quot;full house&quot; pattern of immunoglobulin deposition, including IgG, IgM, IgA, C1q, C3, and kappa and lambda light chains [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/21\" class=\"abstract_t\">21</a>].</p><p/><p>EM in immunoglobulin-positive MPGN typically demonstrates subendothelial and mesangial deposits (<a href=\"image.htm?imageKey=NEPH%2F64411\" class=\"graphic graphic_picture graphicRef64411 \">picture 5</a>). Subepithelial deposits can also be seen with autoimmune diseases. As an example, patients with diffuse proliferative lupus nephritis can also have membranous lupus with subepithelial deposits (<a href=\"image.htm?imageKey=NEPH%2F69348\" class=\"graphic graphic_picture graphicRef69348 \">picture 6</a>) [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/2\" class=\"abstract_t\">2</a>]. However, EM alone does not differentiate between immune complex-mediated and complement-mediated MPGN.</p><p>EM may suggest certain underlying diseases. As examples, tubuloreticular structures in endothelial cells in MPGN are suggestive of lupus nephritis (<a href=\"image.htm?imageKey=NEPH%2F79072\" class=\"graphic graphic_picture graphicRef79072 \">picture 7</a>), and a fingerprint pattern associated with cryoprecipitates is seen in mixed cryoglobulinemia (<a href=\"image.htm?imageKey=NEPH%2F81450\" class=\"graphic graphic_picture graphicRef81450 \">picture 8</a>) or rarely in lupus nephritis associated with cryoglobulinemia [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/22\" class=\"abstract_t\">22</a>]. (See <a href=\"topic.htm?path=diagnosis-and-classification-of-renal-disease-in-systemic-lupus-erythematosus#H7\" class=\"medical medical_review\">&quot;Diagnosis and classification of renal disease in systemic lupus erythematosus&quot;, section on 'Classification'</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-the-mixed-cryoglobulinemia-syndrome-essential-mixed-cryoglobulinemia#H8\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)&quot;, section on 'Renal disease'</a>.) </p><p class=\"headingAnchor\" id=\"H261825925\"><span class=\"h3\">Infections</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immune complex-mediated MPGN is most commonly secondary to hepatitis C and B viral infections [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/2,14,23-25\" class=\"abstract_t\">2,14,23-25</a>]. The incidence of HCV-associated MPGN varies with location. As examples, HCV appears to be a common cause of MPGN in Japan [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/12\" class=\"abstract_t\">12</a>] but is an uncommon cause in France and South Africa [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/26,27\" class=\"abstract_t\">26,27</a>]. HCV-induced MPGN is typically associated with mixed cryoglobulinemia. (See <a href=\"topic.htm?path=overview-of-renal-disease-associated-with-hepatitis-c-virus-infection#H3\" class=\"medical medical_review\">&quot;Overview of renal disease associated with hepatitis C virus infection&quot;, section on 'Membranoproliferative glomerulonephritis without cryoglobulins'</a> and <a href=\"topic.htm?path=renal-disease-associated-with-hepatitis-b-virus-infection#H4\" class=\"medical medical_review\">&quot;Renal disease associated with hepatitis B virus infection&quot;, section on 'Membranoproliferative glomerulonephritis (MPGN)'</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-the-mixed-cryoglobulinemia-syndrome-essential-mixed-cryoglobulinemia#H8\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)&quot;, section on 'Renal disease'</a>.) </p><p>In addition to HCV, chronic bacterial (eg, endocarditis, shunt nephritis, abscesses), fungal, and, particularly in the developing world, parasitic infections (eg, schistosomiasis, echinococcosis) can cause MPGN [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/12,13,28-30\" class=\"abstract_t\">12,13,28-30</a>]. (See <a href=\"topic.htm?path=renal-disease-in-the-setting-of-infective-endocarditis-or-an-infected-ventriculoatrial-shunt#H2\" class=\"medical medical_review\">&quot;Renal disease in the setting of infective endocarditis or an infected ventriculoatrial shunt&quot;, section on 'Clinical features and renal biopsy findings'</a> and <a href=\"topic.htm?path=schistosomiasis-and-glomerular-disease#H3\" class=\"medical medical_review\">&quot;Schistosomiasis and glomerular disease&quot;, section on 'Clinicopathologic manifestations'</a>.)</p><p class=\"headingAnchor\" id=\"H455985652\"><span class=\"h3\">Autoimmune disorders</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immune complex-mediated MPGN is observed in patients with systemic lupus erythematosus (particularly in the chronic phase of lupus nephritis) and, less often, Sj&ouml;gren's syndrome or rheumatoid arthritis [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/18,19,31,32\" class=\"abstract_t\">18,19,31,32</a>]. (See <a href=\"topic.htm?path=diagnosis-and-classification-of-renal-disease-in-systemic-lupus-erythematosus#H11\" class=\"medical medical_review\">&quot;Diagnosis and classification of renal disease in systemic lupus erythematosus&quot;, section on 'Diffuse lupus nephritis (class IV)'</a> and <a href=\"topic.htm?path=renal-disease-in-sjogrens-syndrome#H6\" class=\"medical medical_review\">&quot;Renal disease in Sj&ouml;gren's syndrome&quot;, section on 'Glomerular disease'</a>.)</p><p class=\"headingAnchor\" id=\"H455985660\"><span class=\"h3\">Monoclonal gammopathies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Monoclonal gammopathies are an important cause of MPGN and can be associated on immunofluorescence microscopy with either monoclonal immunoglobulin deposition, as discussed in this section [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/17,33-40\" class=\"abstract_t\">17,33-40</a>], or isolated complement deposition in dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), as discussed below. (See <a href=\"#H12\" class=\"local\">'Complement-mediated MPGN'</a> below and <a href=\"#H119004535\" class=\"local\">'C3 dense deposit disease'</a> below.) </p><p>In a retrospective review of renal biopsies performed at the Mayo Clinic, 28 of 68 patients (41 percent) who had a diagnosis of MPGN and were not infected with either hepatitis B or C virus had a monoclonal gammopathy, as determined by serum <span class=\"nowrap\">and/or</span> urine electrophoresis [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/17\" class=\"abstract_t\">17</a>]. A diagnosis of monoclonal gammopathy of undetermined significance (MGUS) was made in 16 patients; the 12 remaining patients had lymphoma or multiple myeloma. However, by definition, the diagnosis of MGUS requires that end-organ damage not be present. We prefer the term &quot;monoclonal gammopathy-associated MPGN&quot; since the term &quot;MGUS&quot; refers to undetermined hematologic significance, not the presence of nonhematologic manifestations. The term &quot;monoclonal gammopathy of renal significance&quot; (MGRS) has also been proposed to describe cases in which the monoclonal gammopathy is determined to have relevance to kidney disease [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/41\" class=\"abstract_t\">41</a>]. (See <a href=\"topic.htm?path=diagnosis-of-monoclonal-gammopathy-of-undetermined-significance#H90176110\" class=\"medical medical_review\">&quot;Diagnosis of monoclonal gammopathy of undetermined significance&quot;, section on 'Diagnostic criteria'</a> and <a href=\"topic.htm?path=diagnosis-and-treatment-of-monoclonal-gammopathy-of-renal-significance\" class=\"medical medical_review\">&quot;Diagnosis and treatment of monoclonal gammopathy of renal significance&quot;</a>.)</p><p>The clinical features and prognosis of MPGN associated with monoclonal gammopathy were described in a study of 37 patients who had monoclonal IgG deposits [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/38\" class=\"abstract_t\">38</a>]. Nephrotic syndrome, renal insufficiency, and hematuria were present in 49, 68, and 77 percent, respectively. Of 32 patients who were followed for over two years, 22 percent progressed to end-stage renal disease (ESRD), 38 percent had complete or partial recovery, and 38 percent had persistent renal dysfunction. Only one patient had multiple myeloma. </p><p>Cases of MPGN in patients with chronic lymphocytic leukemia have also been described, usually in association with mixed cryoglobulinemia or noncryoprecipitating monoclonal IgG or IgM [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/40,42\" class=\"abstract_t\">40,42</a>]. (See <a href=\"topic.htm?path=clinical-presentation-pathologic-features-diagnosis-and-differential-diagnosis-of-chronic-lymphocytic-leukemia#H602942875\" class=\"medical medical_review\">&quot;Clinical presentation, pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia&quot;, section on 'Other organ involvement'</a>.)</p><p>Patients with MPGN associated with monoclonal immunoglobulin deposits have a high rate of recurrent disease (approximately 70 percent) after kidney transplantation [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/43,44\" class=\"abstract_t\">43,44</a>]. Recurrence typically occurs early posttransplant and is characterized by an aggressive course and high risk of graft failure [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/43,44\" class=\"abstract_t\">43,44</a>]. Biopsy of the allograft often shows a mesangial proliferative pattern of injury that subsequently progresses to an MPGN pattern. Glomerular deposits are most often composed of IgG3 kappa, although other immunoglobulin isotypes <span class=\"nowrap\">and/or</span> light chains have also been identified in the deposits; the prognostic implications of these immunoglobulin variations are unclear [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/43\" class=\"abstract_t\">43</a>]. In two-thirds of cases, a monoclonal immunoglobulin cannot be detected in the serum or urine, and bone marrow biopsy shows no evidence of a plasma cell disorder. In the other one-third of the patients, a monoclonal protein can be identified in the serum or urine, but most patients have an MGRS rather than multiple myeloma. (See <a href=\"topic.htm?path=recurrence-of-idiopathic-immune-complex-mediated-membranoproliferative-glomerulonephritis-mpgn-after-transplantation\" class=\"medical medical_review\">&quot;Recurrence of idiopathic immune complex-mediated membranoproliferative glomerulonephritis (MPGN) after transplantation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4155923547\"><span class=\"h4\">MPGN with masked deposits</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In rare cases, patients with MPGN associated with monoclonal gammopathy may present with isolated C3 deposits with no staining of immunoglobulins by standard immunofluorescence techniques [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/45\" class=\"abstract_t\">45</a>]. Immunofluorescence on formalin-fixed, paraffin-embedded tissue after pronase digestion may reveal the presence of &quot;masked&quot; monoclonal immunoglobulin deposits. Positive staining for C4d, a byproduct of the classic and lectin complement pathways, can also be helpful in detecting &quot;masked&quot; immune deposits [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/46,47\" class=\"abstract_t\">46,47</a>]. The immunoglobulin detected within glomerular deposits typically matches the monoclonal protein identified by serum or urine immunofixation in these patients. Failure to identify these &quot;masked&quot; monoclonal immunoglobulins can result in missing the diagnosis of monoclonal gammopathy-associated MPGN and incorrectly diagnosing these patients as having only C3GN. It is important that these cases are not misdiagnosed as C3 glomerulopathy, as most are associated with a low-grade lymphoma or plasma cell dyscrasia. (See <a href=\"topic.htm?path=diagnosis-and-treatment-of-monoclonal-gammopathy-of-renal-significance#H2364316923\" class=\"medical medical_review\">&quot;Diagnosis and treatment of monoclonal gammopathy of renal significance&quot;, section on 'Diagnosis of MGRS'</a>.)</p><p class=\"headingAnchor\" id=\"H274990906\"><span class=\"h3\">Rare causes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rare causes of MPGN include non-Hodgkin lymphoma [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/48\" class=\"abstract_t\">48</a>], renal cell carcinoma [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/49\" class=\"abstract_t\">49</a>], snake venom [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/50\" class=\"abstract_t\">50</a>], splenorenal shunt surgery for portal hypertension [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/51\" class=\"abstract_t\">51</a>], melanoma [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/52\" class=\"abstract_t\">52</a>], alpha-1-antitrypsin deficiency, and cryoglobulinemic glomerulonephritis [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/53\" class=\"abstract_t\">53</a>]. Idiopathic MPGN is a diagnosis of exclusion [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/54\" class=\"abstract_t\">54</a>]. (See <a href=\"topic.htm?path=extrapulmonary-manifestations-of-alpha-1-antitrypsin-deficiency#H11\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of alpha-1 antitrypsin deficiency&quot;, section on 'Glomerulonephritis'</a>.) </p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Complement-mediated MPGN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Complement-mediated MPGN is less common than immune complex-mediated MPGN and results from dysregulation and persistent activation of the alternative complement pathway [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/8,9,30,31\" class=\"abstract_t\">8,9,30,31</a>]. This form of MPGN is due to the deposition of complement products along the capillary walls and in the mesangium. Complement-mediated MPGN can be subdivided into C3 glomerulopathy and C4 glomerulopathy based upon the complement product identified within glomerular deposits. In C3 glomerulopathy, immunofluorescence microscopy of kidney sections demonstrates predominantly bright staining for C3, with minimal or no immunoglobulin staining, in the mesangium and along the capillary walls (<a href=\"image.htm?imageKey=NEPH%2F76040\" class=\"graphic graphic_picture graphicRef76040 \">picture 9</a>) [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/55\" class=\"abstract_t\">55</a>]. C4 glomerulopathy is characterized by bright staining for C4d, a degradation product of C4, with minimal or no C3 or immunoglobulin staining (<a href=\"image.htm?imageKey=NEPH%2F107059\" class=\"graphic graphic_picture graphicRef107059 \">picture 10</a>).</p><p>Complement-mediated MPGN may be further classified based upon ultrastructural features observed on EM as DDD or C3 (or C4) glomerulonephritis. Some genetic mutations that have been associated with these disorders are also associated with atypical hemolytic uremic syndrome [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/56\" class=\"abstract_t\">56</a>]. (See <a href=\"topic.htm?path=complement-mediated-hemolytic-uremic-syndrome\" class=\"medical medical_review\">&quot;Complement-mediated hemolytic uremic syndrome&quot;</a>.) </p><p>As mentioned above, hypocomplementemia is a characteristic finding in most patients with MPGN. However, a normal C3 concentration does not exclude complement-mediated MPGN, and it is not unusual to find a normal C3 concentration in the chronic phases of the disease, as in adults with DDD [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/6\" class=\"abstract_t\">6</a>] or patients with C3GN [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/57\" class=\"abstract_t\">57</a>]. (See <a href=\"#H1217072877\" class=\"local\">'Introduction and clinical presentation'</a> above.)</p><p class=\"headingAnchor\" id=\"H3915261863\"><span class=\"h3\">C3 glomerulopathy</span></p><p class=\"headingAnchor\" id=\"H119004535\"><span class=\"h4\">C3 dense deposit disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>C3 DDD (also called MPGN type II) is a rare form of MPGN that affects both children and young adults. It has also been associated with monoclonal gammopathies in older adults [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/58\" class=\"abstract_t\">58</a>]. In the majority of patients, antibodies called C3 nephritic factors (C3Nefs) that stabilize C3 convertase are present in circulation. (See <a href=\"topic.htm?path=c3-glomerulopathies-dense-deposit-disease-and-c3-glomerulonephritis#H4\" class=\"medical medical_review\">&quot;C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis&quot;, section on 'Case studies'</a>.) </p><p>On light microscopy, patterns of injury other than MPGN can also be seen, including mesangial proliferative, diffuse proliferative, crescentic glomerulonephritis, and a sclerosing glomerulopathy. Immunofluorescence microscopy demonstrates C3 deposits, and EM (required to establish the diagnosis) shows the characteristic sausage-shaped, wavy, densely osmophilic deposits along the glomerular basement membranes (GBM) and mesangium (from which the disease receives its name) (<a href=\"image.htm?imageKey=NEPH%2F73319\" class=\"graphic graphic_picture graphicRef73319 \">picture 11</a>). A finding that may be present in C3 DDD that is not seen in other forms of MPGN is drusen on fundoscopic examination. (See <a href=\"topic.htm?path=c3-glomerulopathies-dense-deposit-disease-and-c3-glomerulonephritis\" class=\"medical medical_review\">&quot;C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H455985668\"><span class=\"h4\">C3 glomerulonephritis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>C3GN (also called glomerulonephritis with isolated C3 deposits) is, like C3 DDD, caused by excessive activation of the alternative complement cascade due (in most patients) to mutations in or antibodies to complement regulating proteins [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/8,56,57,59-62\" class=\"abstract_t\">8,56,57,59-62</a>]. C3GN has also been reported in association with monoclonal gammopathies and anti-factor H activity, as well as with inherited disease due to mutations in the CFHR5 gene (CFHR5 nephropathy) and a mutation producing a CFHR1-CFHR3 hybrid gene [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/63,64\" class=\"abstract_t\">63,64</a>]. (See <a href=\"topic.htm?path=diagnosis-and-treatment-of-monoclonal-gammopathy-of-renal-significance\" class=\"medical medical_review\">&quot;Diagnosis and treatment of monoclonal gammopathy of renal significance&quot;</a> and <a href=\"#H37578836\" class=\"local\">'CFHR5 nephropathy'</a> below.) </p><p>Light microscopy often shows an MPGN pattern of injury, although other forms of glomerulonephritis may be seen, including mesangial proliferative, diffuse proliferative, crescentic glomerulonephritis, and a sclerosing glomerulopathy [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/56,59,65-67\" class=\"abstract_t\">56,59,65-67</a>]. C3GN with severe crescentic glomerulonephritis is a rare subtype that more commonly affects children and young adults [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/68\" class=\"abstract_t\">68</a>].</p><p>Immunofluorescence microscopy shows extensive C3 deposition along the capillary walls and mesangium (<a href=\"image.htm?imageKey=NEPH%2F76040\" class=\"graphic graphic_picture graphicRef76040 \">picture 9</a>) with <strong>no</strong> significant immunoglobulin deposition [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/8,56,59,69\" class=\"abstract_t\">8,56,59,69</a>]. EM demonstrates deposits that are similar to those seen with immune complex-mediated MPGN but does not show the typical sausage-shaped intramembranous and mesangial deposits observed in DDD (<a href=\"image.htm?imageKey=NEPH%2F50927\" class=\"graphic graphic_picture graphicRef50927 \">picture 12</a>).</p><p>Patients with C3GN typically present with proteinuria, which can be associated with nephrotic syndrome, hematuria, and variable degrees of hypertension and azotemia. C3 levels are low in less than 50 percent of cases, C4 levels are normal, and some patients have a C3 convertase-stabilizing autoantibody called C3 nephritic factor (or C3NeF), which is also seen in DDD [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/56,59,60\" class=\"abstract_t\">56,59,60</a>]. A normal C3 does not exclude C3GN [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/57,70\" class=\"abstract_t\">57,70</a>]. There may be progression to ESRD, and C3GN can recur after renal transplantation.</p><p>Some patients develop hematuria after an upper respiratory infection (URI). In a report of nine patients who presented with hematuria following a nonstreptococcal URI and had glomerulonephritis on renal biopsy, six had mesangial C3 deposits, and four had hypocomplementemia [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/71\" class=\"abstract_t\">71</a>]. These findings suggest that the patients may have had a form of C3GN that had not been described at the time of publication. In addition, hematuria after a URI is well described in CFHR5 nephropathy, as described in the next section.</p><p class=\"headingAnchor\" id=\"H37578836\"><span class=\"h5\">CFHR5 nephropathy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A familial form of C3GN has been described in patients of Cypriot origin due to a mutation in the gene for complement factor H-related protein 5 (CFHR5) [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/72,73\" class=\"abstract_t\">72,73</a>]. In a cohort of 84 Cypriots with unexplained renal disease, four (5 percent) had CFHR5 nephropathy, as detected by mutation analysis [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/72\" class=\"abstract_t\">72</a>].</p><p>CFHR5 nephropathy has the following genetic features [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/74\" class=\"abstract_t\">74</a>]. Inheritance is autosomal dominant with more than 90 percent penetrance. The mutation involves a genomic duplication in the CFHR5 gene that results in an elongated version of the CFHR5 protein. The mutation is present in approximately 1 in 6500 Cypriots and is associated with an extended haplotype flanking the mutation, pointing toward a common ancestor. </p><p>The clinical manifestations include hematuria in approximately 90 percent, accompanied by proteinuria in 38 percent [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/73\" class=\"abstract_t\">73</a>]. Episodes of macroscopic (gross) hematuria can occur within one to two days of a URI and can be recurrent [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/72\" class=\"abstract_t\">72</a>]. The serum C3 concentrations at presentation have been poorly characterized among patients with CFHR5 nephropathy. Among CHFR5 mutation carriers over age 50 years, men are much more likely than women to develop chronic kidney disease (80 versus 21 percent) and ESRD (78 versus 4 percent) [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/73\" class=\"abstract_t\">73</a>]. The development of proteinuria (greater than 1 to 1.5 <span class=\"nowrap\">g/day)</span> is a major predictor of a progressive disease [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/73\" class=\"abstract_t\">73</a>]. Recurrent nephropathy can occur in transplanted kidneys [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/75\" class=\"abstract_t\">75</a>]. There is no treatment of proven efficacy.</p><p class=\"headingAnchor\" id=\"H1217075066\"><span class=\"h5\">Distinction from postinfectious glomerulonephritis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some patients with MPGN have subepithelial and subendothelial deposits on EM (ie, MPGN type III as described below) and are complement positive but immunoglobulin negative by immunofluorescence microscopy. Some of these cases have been attributed to resolving postinfectious glomerulonephritis because of the presence of subepithelial deposits on EM, even in the absence of a history of recent infection. Atypical, persistent, or resolving postinfectious glomerulonephritis are terms that have been used to describe such cases. In such cases, bright C3 staining and lack of significant immunoglobulin staining raise the possibility of C3GN. Consistent with this hypothesis, abnormalities in the alternative complement pathway have been found in many of these patients [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/57,76-79\" class=\"abstract_t\">57,76-79</a>] and likely represent cases of undiagnosed C3GN [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/79\" class=\"abstract_t\">79</a>]. By contrast, postinfectious glomerulonephritis is associated with both bright C3 staining and IgG deposition (<a href=\"image.htm?imageKey=NEPH%2F56846\" class=\"graphic graphic_picture graphicRef56846 \">picture 13</a>). </p><p>Findings on EM may also help to distinguish C3GN from postinfectious glomerulonephritis. C3GN is usually associated with abundant large mesangial, subendothelial, and occasionally subepithelial or intramembranous deposits that have a fuzzy amorphous lobular quality (<a href=\"image.htm?imageKey=NEPH%2F50927\" class=\"graphic graphic_picture graphicRef50927 \">picture 12</a>). This is in contrast to the well-demarcated subepithelial humps seen in postinfectious glomerulonephritis (<a href=\"image.htm?imageKey=NEPH%2F76739\" class=\"graphic graphic_picture graphicRef76739 \">picture 14</a>). (See <a href=\"topic.htm?path=poststreptococcal-glomerulonephritis#H5\" class=\"medical medical_review\">&quot;Poststreptococcal glomerulonephritis&quot;, section on 'Pathology'</a>.)</p><p class=\"headingAnchor\" id=\"H2818828479\"><span class=\"h3\">C4 glomerulopathy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>C4 glomerulopathy, which includes C4 DDD and C4GN, is a rare disorder characterized by the glomerular deposition of C4 in the absence of C3, C1q, and immunoglobulin [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/80,81\" class=\"abstract_t\">80,81</a>]. Unlike patients with C3 glomerulopathy, those with C4 glomerulopathy do not have congenital or acquired defects in the alternative pathway of complement; however, they may have an overactive lectin pathway of complement. A more detailed discussion of C4 glomerulopathy is presented separately. (See <a href=\"topic.htm?path=c4-glomerulopathy\" class=\"medical medical_review\">&quot;C4 glomerulopathy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H455985677\"><span class=\"h2\">MPGN without immunoglobulin or complement deposition</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A histologic pattern that may resemble MPGN on light microscopy can be seen in the healing phase of thrombotic microangiopathies (eg, thrombotic thrombocytopenia purpura-hemolytic uremic syndrome), antiphospholipid antibody syndrome, nephropathy associated with bone marrow transplantation, chronic renal allograft nephropathy, radiation nephritis, and malignant hypertension. (See <a href=\"topic.htm?path=antiphospholipid-syndrome-and-the-kidney#H2\" class=\"medical medical_review\">&quot;Antiphospholipid syndrome and the kidney&quot;, section on 'Renal manifestations of antiphospholipid syndrome'</a> and <a href=\"topic.htm?path=kidney-disease-following-hematopoietic-cell-transplantation#H9\" class=\"medical medical_review\">&quot;Kidney disease following hematopoietic cell transplantation&quot;, section on 'Thrombotic microangiopathy'</a> and <a href=\"topic.htm?path=chronic-renal-allograft-nephropathy#H3\" class=\"medical medical_review\">&quot;Chronic renal allograft nephropathy&quot;, section on 'Pathology'</a> and <a href=\"topic.htm?path=acquired-ttp-clinical-manifestations-and-diagnosis#H1145369\" class=\"medical medical_review\">&quot;Acquired TTP: Clinical manifestations and diagnosis&quot;, section on 'Neurologic and other organ involvement'</a>.)</p><p>The common underlying cause of the MPGN pattern in such patients is endothelial injury followed by reparative changes. Immunofluorescence microscopy does not show significant immunoglobulin or complement deposition in the glomeruli, and EM does not show electron dense deposits along the capillary walls.</p><p class=\"headingAnchor\" id=\"H559999613\"><span class=\"h1\">CLASSIFICATION BASED UPON ELECTRON MICROSCOPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>MPGN was initially classified into types I, II, and III based upon electron microscopy (EM). However, this classification has important limitations, and we prefer the classification based upon immunofluorescence microscopy. (See <a href=\"#H92986221\" class=\"local\">'Limitations of this classification'</a> below.)</p><p class=\"headingAnchor\" id=\"H92986245\"><span class=\"h2\">MPGN type I</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>MPGN type I is characterized by discrete immune deposits in the mesangium and subendothelial space, similar to that seen in lupus nephritis, that are thought to reflect the deposition of circulating immune complexes (<a href=\"image.htm?imageKey=NEPH%2F64411\" class=\"graphic graphic_picture graphicRef64411 \">picture 5</a>).</p><p class=\"headingAnchor\" id=\"H92986252\"><span class=\"h2\">MPGN type II</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>MPGN type II (dense deposit disease, or DDD) is characterized by continuous, dense ribbon-like deposits along the basement membranes of the glomeruli, tubules, and Bowman's capsule (<a href=\"image.htm?imageKey=NEPH%2F73319\" class=\"graphic graphic_picture graphicRef73319 \">picture 11</a>) [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/3,82,83\" class=\"abstract_t\">3,82,83</a>]. (See <a href=\"topic.htm?path=c3-glomerulopathies-dense-deposit-disease-and-c3-glomerulonephritis\" class=\"medical medical_review\">&quot;C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H92986267\"><span class=\"h2\">MPGN type III</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>MPGN type III is similar to MPGN type I except that subepithelial deposits are noted as well as subendothelial deposits. Based upon the EM findings, MPGN type III is further classified into two principal variants, the Strife and Anders variant and the Burkholder variant, which have different patterns of electron dense deposits and disorganization of the glomerular basement membrane (GBM) [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/5,84-86\" class=\"abstract_t\">5,84-86</a>].</p><p>Many cases of MPGN type III that are immunoglobulin negative but complement positive by immunofluorescence microscopy have been attributed to resolving postinfectious glomerulonephritis because of the presence of subepithelial humps on EM, despite the absence of a history of recent infection. In such cases, bright C3 staining and lack of significant immunoglobulin staining raise the possibility of C3 glomerulonephritis (C3GN). Consistent with this hypothesis, subsequent evaluation demonstrated abnormalities of the alternative complement pathway in many of these patients. (See <a href=\"#H455985668\" class=\"local\">'C3 glomerulonephritis'</a> above.)</p><p class=\"headingAnchor\" id=\"H92986221\"><span class=\"h2\">Limitations of this classification</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Understanding the limitations of the EM classification requires a brief review of complement activation pathways. There are two main pathways: the classic pathway, which is activated when immunoglobulin G (IgG) or IgM antibodies bind to antigens; and the alternative pathway, which does not require the presence of antibodies and can be autoactivated by spontaneous cleavage of C3 to C3b, leading to the formation of C3 convertase (<a href=\"image.htm?imageKey=NEPH%2F59641\" class=\"graphic graphic_figure graphicRef59641 \">figure 1</a>). (See <a href=\"topic.htm?path=overview-and-clinical-assessment-of-the-complement-system#H2\" class=\"medical medical_review\">&quot;Overview and clinical assessment of the complement system&quot;, section on 'Pathways and activating conditions'</a>.)</p><p>The EM-based classification can result in overlap between types I and III. Both types have been considered to be immune complex-mediated glomerulonephritides because of the presence of immune-type electron dense deposits in the mesangium and subendothelial space. However, the following observations suggest that some cases with EM features of MPGN type I or MPGN type III are mediated by complement, not immune complexes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Some cases of MPGN type I have been associated with strong C3 staining without immunoglobulin staining by immunofluorescence microscopy, consistent with a process mediated by complement rather than immune complexes [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/87\" class=\"abstract_t\">87</a>]. (See <a href=\"#H12\" class=\"local\">'Complement-mediated MPGN'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The majority of cases of MPGN type III show strong C3 staining without immunoglobulin staining by immunofluorescence microscopy, again consistent with a process mediated by complement rather than immune complexes.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Markedly depressed serum C3 levels with normal or only mildly decreased serum C4 and C1q levels have been observed in patients with MPGN type I, suggesting possible activation of the alternative rather than the classical complement pathway activated by immune complexes [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/84\" class=\"abstract_t\">84</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A C3 convertase-stabilizing antibody (called C3 nephritic factor or C3NeF) is found in approximately 80 percent of patients with DDD and results in activation of the alternative complement pathway that characterizes DDD. However, different C3 nephritic factors have been identified in some patients with MPGN types I and III [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/88,89\" class=\"abstract_t\">88,89</a>]. (See <a href=\"topic.htm?path=c3-glomerulopathies-dense-deposit-disease-and-c3-glomerulonephritis#H2\" class=\"medical medical_review\">&quot;C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis&quot;, section on 'Pathogenesis'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is an inherited form of MPGN type III that is linked to chromosome 1q32, the locus for the complement receptor family [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/90,91\" class=\"abstract_t\">90,91</a>]. These genes code for a highly homologous group of proteins that regulate C3 convertase activity. Abnormalities in any of these proteins may cause excess circulating C3b, mimicking the action of C3NeF [<a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/90\" class=\"abstract_t\">90</a>]. (See <a href=\"topic.htm?path=regulators-and-receptors-of-the-complement-system\" class=\"medical medical_review\">&quot;Regulators and receptors of the complement system&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2137984988\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-glomerular-disease-in-adults\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Glomerular disease in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H80906099\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with membranoproliferative glomerulonephritis (MPGN) can present with a variety of findings, ranging from microscopic hematuria with or without mild proteinuria to nephrotic syndrome and severe glomerulonephritis with hypertension and a reduced glomerular filtration rate. Hypocomplementemia is a common finding. (See <a href=\"#H1217072877\" class=\"local\">'Introduction and clinical presentation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>MPGN is a pattern of glomerular injury viewed by light microscopy that may be caused by multiple pathogenic processes. MPGN is traditionally classified based upon electron microscopy (EM) findings as MPGN types I, II, and III and as secondary MPGN. An alternative classification system that is based upon the pathogenic process (and often identified by immunofluorescence microscopy) is more valuable for the practicing clinician because it helps direct the correct clinical evaluation and design potential disease-specific treatments. (See <a href=\"#H1\" class=\"local\">'Pathology and pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The two major pathogenetic processes that underlie MPGN are immune complex-mediated and complement-mediated processes. Immune complex-mediated MPGN is characterized by staining for both immunoglobulin and complement by immunofluorescence microscopy, while complement-mediated MPGN is positive predominantly for complement but negative or weakly positive for immunoglobulin staining. Immune complex-mediated disorders are usually viral infection-mediated or associated with monoclonal gammopathy or an autoimmune disease. Complement-mediated MPGN may be further classified based upon EM findings as dense deposit disease (DDD) or C3 (or C4) glomerulonephritis (C3GN or C4GN). (See <a href=\"#H981933439\" class=\"local\">'Classification based upon immunofluorescence microscopy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immunofluorescence microscopy that is characteristic of immune complex-mediated MPGN should lead to evaluation for infections, autoimmune diseases, and monoclonal gammopathies. (See <a href=\"#H455985606\" class=\"local\">'Immune complex-mediated MPGN'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complement-mediated MPGN is less common than immune complex-mediated MPGN. This type of MPGN results from dysregulation and persistent activation of the alternative complement cascade. Immunofluorescence microscopy that is characteristic of complement-mediated MPGN should provoke a search for congenital or acquired defects in the alternative complement cascade. (See <a href=\"#H12\" class=\"local\">'Complement-mediated MPGN'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>MPGN without immunoglobulin or complement deposition can be seen in patients with antiphospholipid syndrome, the healing phase of thrombotic thrombocytopenic <span class=\"nowrap\">purpura/hemolytic-uremic</span> syndrome, scleroderma, and transplant glomerulopathy. (See <a href=\"#H455985677\" class=\"local\">'MPGN without immunoglobulin or complement deposition'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are a variety of rare causes of MPGN. (See <a href=\"#H274990906\" class=\"local\">'Rare causes'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/1\" class=\"nounderline abstract_t\">Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med 2012; 366:1119.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/2\" class=\"nounderline abstract_t\">Rennke HG. Secondary membranoproliferative glomerulonephritis. Kidney Int 1995; 47:643.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/3\" class=\"nounderline abstract_t\">Smith RJ, Alexander J, Barlow PN, et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007; 18:2447.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/4\" class=\"nounderline abstract_t\">Cameron JS, Turner DR, Heaton J, et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 1983; 74:175.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/5\" class=\"nounderline abstract_t\">Strife CF, Jackson EC, McAdams AJ. Type III membranoproliferative glomerulonephritis: long-term clinical and morphologic evaluation. Clin Nephrol 1984; 21:323.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/6\" class=\"nounderline abstract_t\">Nasr SH, Valeri AM, Appel GB, et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 2009; 4:22.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/7\" class=\"nounderline abstract_t\">Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int 2012; 81:434.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/8\" class=\"nounderline abstract_t\">Sethi S, Fervenza FC, Zhang Y, et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 2011; 6:1009.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/9\" class=\"nounderline abstract_t\">Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 2011; 31:341.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/10\" class=\"nounderline abstract_t\">Boseman P, Lewin M, Dillon J, Sethi S. Marfan syndrome, MPGN, and bacterial endocarditis. Am J Kidney Dis 2008; 51:697.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/11\" class=\"nounderline abstract_t\">Hulton SA, Risdon RA, Dillon MJ. Mesangiocapillary glomerulonephritis associated with meningococcal meningitis, C3 nephritic factor and persistently low complement C3 and C5. Pediatr Nephrol 1992; 6:239.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/12\" class=\"nounderline abstract_t\">Yamabe H, Johnson RJ, Gretch DR, et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol 1995; 6:220.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/13\" class=\"nounderline abstract_t\">Yamabe H, Johnson RJ, Gretch DR, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha. Am J Kidney Dis 1995; 25:67.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/14\" class=\"nounderline abstract_t\">Alpers CE, Smith KD. Cryoglobulinemia and renal disease. Curr Opin Nephrol Hypertens 2008; 17:243.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/15\" class=\"nounderline abstract_t\">Vella J, Carmody M, Campbell E, et al. Glomerulonephritis after ventriculo-atrial shunt. QJM 1995; 88:911.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/16\" class=\"nounderline abstract_t\">Adam FU, Torun D, Bolat F, et al. Acute renal failure due to mesangial proliferative glomerulonephritis in a pregnant woman with primary Sj&ouml;gren's syndrome. Clin Rheumatol 2006; 25:75.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/17\" class=\"nounderline abstract_t\">Sethi S, Zand L, Leung N, et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol 2010; 5:770.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/18\" class=\"nounderline abstract_t\">Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65:521.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/19\" class=\"nounderline abstract_t\">Zand L, Fervenza FC, Nasr SH, Sethi S. Membranoproliferative glomerulonephritis associated with autoimmune diseases. J Nephrol 2014; 27:165.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/20\" class=\"nounderline abstract_t\">Glassock RJ, Bargman JM, Palmer BF, et al. Nephrology Quiz and Questionnaire: 2009. Clin J Am Soc Nephrol 2010; 5:1141.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/21\" class=\"nounderline abstract_t\">Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15:241.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/22\" class=\"nounderline abstract_t\">Su CF, Chen HH, Yeh JC, et al. Ultrastructural 'fingerprint' in cryoprecipitates and glomerular deposits: a clinicopathologic analysis of fingerprint deposits. Nephron 2002; 90:37.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/23\" class=\"nounderline abstract_t\">Doutrelepont JM, Adler M, Willems M, et al. Hepatitis C infection and membranoproliferative glomerulonephritis. Lancet 1993; 341:317.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/24\" class=\"nounderline abstract_t\">Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/25\" class=\"nounderline abstract_t\">Smith KD, Alpers CE. Pathogenic mechanisms in membranoproliferative glomerulonephritis. Curr Opin Nephrol Hypertens 2005; 14:396.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/26\" class=\"nounderline abstract_t\">Rostoker G, Deforges L, Ben Maadi A, et al. Low prevalence of antibodies to hepatitis C virus among adult patients with idiopathic membranoproliferative type I glomerulonephritis in France. Nephron 1995; 69:97.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/27\" class=\"nounderline abstract_t\">Madala ND, Naicker S, Singh B, et al. The pathogenesis of membranoproliferative glomerulonephritis in KwaZulu-Natal, South Africa is unrelated to hepatitis C virus infection. Clin Nephrol 2003; 60:69.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/28\" class=\"nounderline abstract_t\">Martinelli R, Noblat AC, Brito E, Rocha H. Schistosoma mansoni-induced mesangiocapillary glomerulonephritis: influence of therapy. Kidney Int 1989; 35:1227.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/29\" class=\"nounderline abstract_t\">Rodrigues VL, Otoni A, Voieta I, et al. Glomerulonephritis in schistosomiasis mansoni: a time to reappraise. Rev Soc Bras Med Trop 2010; 43:638.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/30\" class=\"nounderline abstract_t\">Rinc&oacute;n B, Bernis C, Garcia A, Traver JA. Mesangiocapillary glomerulonephritis associated with hydatid disease. Nephrol Dial Transplant 1993; 8:783.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/31\" class=\"nounderline abstract_t\">Goules A, Masouridi S, Tzioufas AG, et al. Clinically significant and biopsy-documented renal involvement in primary Sj&ouml;gren syndrome. Medicine (Baltimore) 2000; 79:241.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/32\" class=\"nounderline abstract_t\">Cortez MS, Sturgill BC, Bolton WK. Membranoproliferative glomerulonephritis with primary Sj&ouml;gren's syndrome. Am J Kidney Dis 1995; 25:632.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/33\" class=\"nounderline abstract_t\">Salant DJ, Sanchorawala V, D'Agati VD. A case of atypical light chain deposition disease--diagnosis and treatment. Clin J Am Soc Nephrol 2007; 2:858.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/34\" class=\"nounderline abstract_t\">Alpers CE, Tu WH, Hopper J Jr, Biava CG. Single light chain subclass (kappa chain) immunoglobulin deposition in glomerulonephritis. Hum Pathol 1985; 16:294.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/35\" class=\"nounderline abstract_t\">Chang A, Peutz-Kootstra CJ, Richardson CA, Alpers CE. Expanding the pathologic spectrum of light chain deposition disease: a rare variant with clinical follow-up of 7 years. Mod Pathol 2005; 18:998.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/36\" class=\"nounderline abstract_t\">Soares SM, Lager DJ, Leung N, et al. A proliferative glomerulonephritis secondary to a monoclonal IgA. Am J Kidney Dis 2006; 47:342.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/37\" class=\"nounderline abstract_t\">Nasr SH, Markowitz GS, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int 2004; 65:85.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/38\" class=\"nounderline abstract_t\">Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 2009; 20:2055.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/39\" class=\"nounderline abstract_t\">Masai R, Wakui H, Komatsuda A, et al. Characteristics of proliferative glomerulo-nephritis with monoclonal IgG deposits associated with membranoproliferative features. Clin Nephrol 2009; 72:46.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/40\" class=\"nounderline abstract_t\">Moulin B, Ronco PM, Mougenot B, et al. Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney Int 1992; 42:127.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/41\" class=\"nounderline abstract_t\">Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012; 120:4292.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/42\" class=\"nounderline abstract_t\">Barbour SJ, Beaulieu MC, Zalunardo NY, Magil AB. Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases. Nephrol Dial Transplant 2011; 26:2712.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/43\" class=\"nounderline abstract_t\">Nasr SH, Sethi S, Cornell LD, et al. Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft. Clin J Am Soc Nephrol 2011; 6:122.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/44\" class=\"nounderline abstract_t\">Lorenz EC, Sethi S, Leung N, et al. Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney Int 2010; 77:721.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/45\" class=\"nounderline abstract_t\">Larsen CP, Messias NC, Walker PD, et al. Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney Int 2015; 88:867.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/46\" class=\"nounderline abstract_t\">Sethi S, Hernandez LH, Alexander MP, Fervenza FC. C4d as a marker for masked immune deposits. Kidney Int 2016; 90:223.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/47\" class=\"nounderline abstract_t\">Sethi S, Nasr SH, De Vriese AS, Fervenza FC. C4d as a Diagnostic Tool in Proliferative GN. J Am Soc Nephrol 2015; 26:2852.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/48\" class=\"nounderline abstract_t\">Rault R, Holley JL, Banner BF, el-Shahawy M. Glomerulonephritis and non-Hodgkin's lymphoma: a report of two cases and review of the literature. Am J Kidney Dis 1992; 20:84.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/49\" class=\"nounderline abstract_t\">Ahmed M, Solangi K, Abbi R, Adler S. Nephrotic syndrome, renal failure, and renal malignancy: an unusual tumor-associated glomerulonephritis. J Am Soc Nephrol 1997; 8:848.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/50\" class=\"nounderline abstract_t\">Kanjanabuch T, Sitprija V. Snakebite nephrotoxicity in Asia. Semin Nephrol 2008; 28:363.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/51\" class=\"nounderline abstract_t\">Dash SC, Bhuyan UN, Dinda AK, et al. Increased incidence of glomerulonephritis following spleno-renal shunt surgery in non-cirrhotic portal fibrosis. Kidney Int 1997; 52:482.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/52\" class=\"nounderline abstract_t\">Olson JL, Philips TM, Lewis MG, Solez K. Malignant melanoma with renal dense deposits containing tumor antigens. Clin Nephrol 1979; 12:74.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/53\" class=\"nounderline abstract_t\">Sethi S, Theis JD, Vrana JA, et al. Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy. Clin J Am Soc Nephrol 2013; 8:915.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/54\" class=\"nounderline abstract_t\">Fervenza FC, Sethi S, Glassock RJ. Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol Dial Transplant 2012; 27:4288.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/55\" class=\"nounderline abstract_t\">Pickering MC, D'Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int 2013; 84:1079.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/56\" class=\"nounderline abstract_t\">Servais A, Fr&eacute;meaux-Bacchi V, Lequintrec M, et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007; 44:193.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/57\" class=\"nounderline abstract_t\">Sethi S, Fervenza FC, Zhang Y, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012; 82:465.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/58\" class=\"nounderline abstract_t\">Sethi S, Sukov WR, Zhang Y, et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis 2010; 56:977.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/59\" class=\"nounderline abstract_t\">Fakhouri F, Fr&eacute;meaux-Bacchi V, No&euml;l LH, et al. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6:494.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/60\" class=\"nounderline abstract_t\">Habbig S, Mihatsch MJ, Heinen S, et al. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 2009; 75:1230.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/61\" class=\"nounderline abstract_t\">Fakhouri F, de Jorge EG, Brune F, et al. Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int 2010; 78:279.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/62\" class=\"nounderline abstract_t\">Zand L, Kattah A, Fervenza FC, et al. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis 2013; 62:506.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/63\" class=\"nounderline abstract_t\">Bridoux F, Desport E, Fr&eacute;meaux-Bacchi V, et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol 2011; 6:2165.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/64\" class=\"nounderline abstract_t\">Malik TH, Lavin PJ, Goicoechea de Jorge E, et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol 2012; 23:1155.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/65\" class=\"nounderline abstract_t\">Walker PD. Dense deposit disease: new insights. Curr Opin Nephrol Hypertens 2007; 16:204.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/66\" class=\"nounderline abstract_t\">Servais A, No&euml;l LH, Dragon-Durey MA, et al. Heterogeneous pattern of renal disease associated with homozygous factor H deficiency. Hum Pathol 2011; 42:1305.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/67\" class=\"nounderline abstract_t\">Pickering M, Cook HT. Complement and glomerular disease: new insights. Curr Opin Nephrol Hypertens 2011; 20:271.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/68\" class=\"nounderline abstract_t\">Ravindran A, Fervenza FC, Smith RJH, Sethi S. C3 glomerulonephritis with a severe crescentic phenotype. Pediatr Nephrol 2017; 32:1625.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/69\" class=\"nounderline abstract_t\">D'Agati VD, Bomback AS. C3 glomerulopathy: what's in a name? Kidney Int 2012; 82:379.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/70\" class=\"nounderline abstract_t\">Servais A, No&euml;l LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82:454.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/71\" class=\"nounderline abstract_t\">Smith MC, Cooke JH, Zimmerman DM, et al. Asymptomatic glomerulonephritis after nonstreptococcal upper respiratory infections. Ann Intern Med 1979; 91:697.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/72\" class=\"nounderline abstract_t\">Gale DP, de Jorge EG, Cook HT, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010; 376:794.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/73\" class=\"nounderline abstract_t\">Athanasiou Y, Voskarides K, Gale DP, et al. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 2011; 6:1436.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/74\" class=\"nounderline abstract_t\">Gale DP, Pickering MC. Regulating complement in the kidney: insights from CFHR5 nephropathy. Dis Model Mech 2011; 4:721.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/75\" class=\"nounderline abstract_t\">Vernon KA, Gale DP, de Jorge EG, et al. Recurrence of complement factor H-related protein 5 nephropathy in a renal transplant. Am J Transplant 2011; 11:152.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/76\" class=\"nounderline abstract_t\">Fr&eacute;meaux-Bacchi V, Weiss L, Demouchy C, et al. Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity. Nephrol Dial Transplant 1994; 9:1747.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/77\" class=\"nounderline abstract_t\">Halbwachs L, Leveill&eacute; M, Lesavre P, et al. Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme. J Clin Invest 1980; 65:1249.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/78\" class=\"nounderline abstract_t\">Glovsky MM, Ward PA, Johnson KJ. Complement determinations in human disease. Ann Allergy Asthma Immunol 2004; 93:513.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/79\" class=\"nounderline abstract_t\">Sethi S, Fervenza FC, Zhang Y, et al. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int 2013; 83:293.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/80\" class=\"nounderline abstract_t\">Sethi S, Sullivan A, Smith RJ. C4 dense-deposit disease. N Engl J Med 2014; 370:784.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/81\" class=\"nounderline abstract_t\">Sethi S, Quint PS, O'Seaghdha CM, et al. C4 Glomerulopathy: A Disease Entity Associated With&nbsp;C4d&nbsp;Deposition. Am J Kidney Dis 2016; 67:949.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/82\" class=\"nounderline abstract_t\">Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005; 16:1392.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/83\" class=\"nounderline abstract_t\">Sethi S, Gamez JD, Vrana JA, et al. Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int 2009; 75:952.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/84\" class=\"nounderline abstract_t\">Strife CF, McEnery PT, McAdams AJ, West CD. Membranoproliferative glomerulonephritis with disruption of the glomerular basement membrane. Clin Nephrol 1977; 7:65.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/85\" class=\"nounderline abstract_t\">Burkholder PM, Marchand A, Krueger RP. Mixed membranous and proliferative glomerulonephritis. A correlative light, immunofluorescence, and electron microscopic study. Lab Invest 1970; 23:459.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/86\" class=\"nounderline abstract_t\">Anders D. [Membranoproliferative glomerulonephritis]. Dtsch Med Wochenschr 1977; 102:1295.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/87\" class=\"nounderline abstract_t\">Levy M, Gubler MC, Sich M, et al. Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (Type I MPGN). Clin Immunol Immunopathol 1978; 10:477.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/88\" class=\"nounderline abstract_t\">Clardy CW, Forristal J, Strife CF, West CD. A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III. Clin Immunol Immunopathol 1989; 50:333.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/89\" class=\"nounderline abstract_t\">Strife CF, Prada AL, Clardy CW, et al. Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis. J Pediatr 1990; 116:S98.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/90\" class=\"nounderline abstract_t\">Neary JJ, Conlon PJ, Croke D, et al. Linkage of a gene causing familial membranoproliferative glomerulonephritis type III to chromosome 1. J Am Soc Nephrol 2002; 13:2052.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis/abstract/91\" class=\"nounderline abstract_t\">Neary J, Dorman A, Campbell E, et al. Familial membranoproliferative glomerulonephritis type III. Am J Kidney Dis 2002; 40:E1.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3055 Version 21.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H80906099\"><span>SUMMARY</span></a></li><li><a href=\"#H1217072877\" id=\"outline-link-H1217072877\">INTRODUCTION AND CLINICAL PRESENTATION</a></li><li><a href=\"#H1\" id=\"outline-link-H1\">PATHOLOGY AND PATHOGENESIS</a></li><li><a href=\"#H981933439\" id=\"outline-link-H981933439\">CLASSIFICATION BASED UPON IMMUNOFLUORESCENCE MICROSCOPY</a><ul><li><a href=\"#H455985606\" id=\"outline-link-H455985606\">Immune complex-mediated MPGN</a><ul><li><a href=\"#H261825925\" id=\"outline-link-H261825925\">- Infections</a></li><li><a href=\"#H455985652\" id=\"outline-link-H455985652\">- Autoimmune disorders</a></li><li><a href=\"#H455985660\" id=\"outline-link-H455985660\">- Monoclonal gammopathies</a><ul><li><a href=\"#H4155923547\" id=\"outline-link-H4155923547\">MPGN with masked deposits</a></li></ul></li><li><a href=\"#H274990906\" id=\"outline-link-H274990906\">- Rare causes</a></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">Complement-mediated MPGN</a><ul><li><a href=\"#H3915261863\" id=\"outline-link-H3915261863\">- C3 glomerulopathy</a><ul><li><a href=\"#H119004535\" id=\"outline-link-H119004535\">C3 dense deposit disease</a></li><li><a href=\"#H455985668\" id=\"outline-link-H455985668\">C3 glomerulonephritis</a><ul><li><a href=\"#H37578836\" id=\"outline-link-H37578836\">- CFHR5 nephropathy</a></li><li><a href=\"#H1217075066\" id=\"outline-link-H1217075066\">- Distinction from postinfectious glomerulonephritis</a></li></ul></li></ul></li><li><a href=\"#H2818828479\" id=\"outline-link-H2818828479\">- C4 glomerulopathy</a></li></ul></li><li><a href=\"#H455985677\" id=\"outline-link-H455985677\">MPGN without immunoglobulin or complement deposition</a></li></ul></li><li><a href=\"#H559999613\" id=\"outline-link-H559999613\">CLASSIFICATION BASED UPON ELECTRON MICROSCOPY</a><ul><li><a href=\"#H92986245\" id=\"outline-link-H92986245\">MPGN type I</a></li><li><a href=\"#H92986252\" id=\"outline-link-H92986252\">MPGN type II</a></li><li><a href=\"#H92986267\" id=\"outline-link-H92986267\">MPGN type III</a></li><li><a href=\"#H92986221\" id=\"outline-link-H92986221\">Limitations of this classification</a></li></ul></li><li><a href=\"#H2137984988\" id=\"outline-link-H2137984988\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H80906099\" id=\"outline-link-H80906099\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"NEPH/3055|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=NEPH/86556\" class=\"graphic graphic_algorithm\">- Proposed classification of MPGN</a></li></ul></li><li><div id=\"NEPH/3055|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=NEPH/59641\" class=\"graphic graphic_figure\">- Complement pathways 2</a></li></ul></li><li><div id=\"NEPH/3055|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=NEPH/79440\" class=\"graphic graphic_picture\">- Phase-contrast micrograph showing dysmorphic red cells in urine</a></li><li><a href=\"image.htm?imageKey=NEPH/62064\" class=\"graphic graphic_picture\">- Scanning electron micrograph showing dysmorphic red cells</a></li><li><a href=\"image.htm?imageKey=NEPH/55778\" class=\"graphic graphic_picture\">- Photomicrograph of urine sediment with a red cell cast</a></li><li><a href=\"image.htm?imageKey=NEPH/67999\" class=\"graphic graphic_picture\">- MPGN Light I</a></li><li><a href=\"image.htm?imageKey=NEPH/78967\" class=\"graphic graphic_picture\">- MPGN Light II</a></li><li><a href=\"image.htm?imageKey=NEPH/64411\" class=\"graphic graphic_picture\">- Type I MPGN EM</a></li><li><a href=\"image.htm?imageKey=NEPH/69348\" class=\"graphic graphic_picture\">- Electron micrograph of lupus membranous nephropathy</a></li><li><a href=\"image.htm?imageKey=NEPH/79072\" class=\"graphic graphic_picture\">- SLE subendothelial tubuloreticular</a></li><li><a href=\"image.htm?imageKey=NEPH/81450\" class=\"graphic graphic_picture\">- Fingerprint pattern in mixed cryo EM</a></li><li><a href=\"image.htm?imageKey=NEPH/76040\" class=\"graphic graphic_picture\">- C3 glomerulonephritis IF</a></li><li><a href=\"image.htm?imageKey=NEPH/107059\" class=\"graphic graphic_picture\">- Renal histology in C4 dense deposit disease</a></li><li><a href=\"image.htm?imageKey=NEPH/73319\" class=\"graphic graphic_picture\">- Dense deposit disease EM</a></li><li><a href=\"image.htm?imageKey=NEPH/50927\" class=\"graphic graphic_picture\">- C3 glomerulonephritis EM</a></li><li><a href=\"image.htm?imageKey=NEPH/56846\" class=\"graphic graphic_picture\">- Postinfectious GN IF</a></li><li><a href=\"image.htm?imageKey=NEPH/76739\" class=\"graphic graphic_picture\">- Postinfectious GN EM</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-ttp-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Acquired TTP: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antiphospholipid-syndrome-and-the-kidney\" class=\"medical medical_review\">Antiphospholipid syndrome and the kidney</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=c3-glomerulopathies-dense-deposit-disease-and-c3-glomerulonephritis\" class=\"medical medical_review\">C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=c4-glomerulopathy\" class=\"medical medical_review\">C4 glomerulopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chronic-renal-allograft-nephropathy\" class=\"medical medical_review\">Chronic renal allograft nephropathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-the-mixed-cryoglobulinemia-syndrome-essential-mixed-cryoglobulinemia\" class=\"medical medical_review\">Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-pathologic-features-diagnosis-and-differential-diagnosis-of-chronic-lymphocytic-leukemia\" class=\"medical medical_review\">Clinical presentation, pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=complement-mediated-hemolytic-uremic-syndrome\" class=\"medical medical_review\">Complement-mediated hemolytic uremic syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-classification-of-renal-disease-in-systemic-lupus-erythematosus\" class=\"medical medical_review\">Diagnosis and classification of renal disease in systemic lupus erythematosus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-treatment-of-monoclonal-gammopathy-of-renal-significance\" class=\"medical medical_review\">Diagnosis and treatment of monoclonal gammopathy of renal significance</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-monoclonal-gammopathy-of-undetermined-significance\" class=\"medical medical_review\">Diagnosis of monoclonal gammopathy of undetermined significance</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=etiology-and-evaluation-of-hematuria-in-adults\" class=\"medical medical_review\">Etiology and evaluation of hematuria in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-and-treatment-of-membranoproliferative-glomerulonephritis\" class=\"medical medical_review\">Evaluation and treatment of membranoproliferative glomerulonephritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extrapulmonary-manifestations-of-alpha-1-antitrypsin-deficiency\" class=\"medical medical_review\">Extrapulmonary manifestations of alpha-1 antitrypsin deficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=glomerular-disease-evaluation-and-differential-diagnosis-in-adults\" class=\"medical medical_review\">Glomerular disease: Evaluation and differential diagnosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=kidney-disease-following-hematopoietic-cell-transplantation\" class=\"medical medical_review\">Kidney disease following hematopoietic cell transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-and-clinical-assessment-of-the-complement-system\" class=\"medical medical_review\">Overview and clinical assessment of the complement system</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-renal-disease-associated-with-hepatitis-c-virus-infection\" class=\"medical medical_review\">Overview of renal disease associated with hepatitis C virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=poststreptococcal-glomerulonephritis\" class=\"medical medical_review\">Poststreptococcal glomerulonephritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=recurrence-of-idiopathic-immune-complex-mediated-membranoproliferative-glomerulonephritis-mpgn-after-transplantation\" class=\"medical medical_review\">Recurrence of idiopathic immune complex-mediated membranoproliferative glomerulonephritis (MPGN) after transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=regulators-and-receptors-of-the-complement-system\" class=\"medical medical_review\">Regulators and receptors of the complement system</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=renal-disease-associated-with-hepatitis-b-virus-infection\" class=\"medical medical_review\">Renal disease associated with hepatitis B virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=renal-disease-in-sjogrens-syndrome\" class=\"medical medical_review\">Renal disease in Sj&ouml;gren's syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=renal-disease-in-the-setting-of-infective-endocarditis-or-an-infected-ventriculoatrial-shunt\" class=\"medical medical_review\">Renal disease in the setting of infective endocarditis or an infected ventriculoatrial shunt</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=schistosomiasis-and-glomerular-disease\" class=\"medical medical_review\">Schistosomiasis and glomerular disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-glomerular-disease-in-adults\" class=\"medical medical_society_guidelines\">Society guideline links: Glomerular disease in adults</a></li></ul></div></div>","javascript":null}